Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MOR NYSE:SBS TSE:SHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$19.75-2.1%$20.70$13.87▼$22.18$13.79B0.731.08 million shs696,288 shsSHLSource Energy ServicesC$0.00C$0.00▼C$0.00N/AN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%+0.58%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp-2.25%-1.64%-6.41%+5.54%+30.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp1.9446 of 5 stars0.04.02.50.02.40.01.3SHLSource Energy ServicesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMORMorphoSys 0.00N/AN/AN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp 4.00Strong BuyN/AN/ASHLSource Energy Services 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$6.70B2.01$2.08 per share9.48$10.02 per share1.97SHLSource Energy ServicesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$1.78B$2.687.3717.48N/A28.70%29.18%14.03%8/14/2025 (Estimated)SHLSource Energy ServicesN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest DRW3, SBS, SHL, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.39N/AN/AN/A$6.63 billionN/A5/12/2025Q1 2025SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.38$0.37-$0.01$0.37$7.67 billion$1.04 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMORMorphoSysN/AN/AN/AN/AN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.381.92%N/A14.18%N/ASHLSource Energy ServicesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMORMorphoSys4.981.381.38SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp0.600.890.89SHLSource Energy ServicesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMORMorphoSys18.38%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp10.62%SHLSource Energy ServicesN/AInsider OwnershipCompanyInsider OwnershipMORMorphoSys0.05%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp1.00%SHLSource Energy ServicesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableSBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp10,552683.51 million676.68 millionOptionableSHLSource Energy ServicesN/AN/AN/ANot OptionableDRW3, SBS, SHL, and MOR HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRW3, SBS, SHL, and MOR Company DescriptionsMorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/17/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp NYSE:SBS$19.75 -0.43 (-2.13%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$19.85 +0.10 (+0.51%) As of 07/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Companhia de Saneamento Basico do Estado de Sao Paulo SABESP engages in the provision of water and sewage service. It also offers advisory services on the rational use of water, planning and commercial, and financial and operational management. The company was founded on September 6, 1973 and is headquartered in São Paulo, Brazil.Source Energy Services TSE:SHLHomeland Nickel Inc. is a mineral exploration company. It is focused on critical metal resources with nickel projects in Oregon, United States and copper projects in Newfoundland, Canada. Its projects include Cleopatra, Red Flat Nickel Property, Shamrock Property, and Eight Dollar Mountain. The Cleopatra property is located in southwest Oregon and consists of 139 lode mining claims covering a total area of 1,162 hectares (2,872 acres). The Red Flat Nickel property is located in southwest Oregon 15 kilometers (km) east of Gold Beach and 480 km south of the City of Portland. The Eight Dollar Mountain property is located in Josephine County, Oregon. The Eight Dollar Mountain property consists of 115 claims totaling 962 hectares (2,376 acres). The Shamrock Property consists of 40 unpatented load claims, accessible by paved road, covering 758 acres and located 20 miles northwest of Medford, Oregon. It also owns a 70% interest in the Great Burnt and South Pond copper and gold properties. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
